Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via the Lyn-PI3K/AKT pathway

Inhibition of SRC Corrects GM-CSF Hypersensitivity That Underlies Juvenile Myelomonocytic Leukemia

(2013) S. Bunda et al.   CANCER RESEARCH

A versatile lentiviral expression system to identify mammalian protein–protein interactions

(2012) Anthony B. Mak et al.   METHODS

Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice

(2011) M. E. Balasis et al.   CLINICAL CANCER RESEARCH

A Phase I Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias

(2011) J. E. Lancet et al.   CLINICAL CANCER RESEARCH

Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I Consortium

(2011) Richard Aplenc et al.   JOURNAL OF CLINICAL ONCOLOGY

The Src Family Kinase Fgr Is Critical for Activation of Mast Cells and IgE-Mediated Anaphylaxis in Mice

(2011) J. H. Lee et al.   JOURNAL OF IMMUNOLOGY

A MEK Inhibitor Abrogates Myeloproliferative Disease in Kras Mutant Mice

(2011) N. Lyubynska et al.   Science Translational Medicine

Childhood Myelodysplastic Syndrome: Focus on the Approach to Diagnosis and Treatment of Juvenile Myelomonocytic Leukemia

(2011) M. L. Loh   Hematology-American Society of Hematology Education Program

Alternative modes of GM-CSF receptor activation revealed using activated mutants of the common  -subunit

(2010) M. Perugini et al.   BLOOD

Molecular basis of juvenile myelomonocytic leukemia

(2010) A. C.H. de Vries et al.   HAEMATOLOGICA

Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia

(2010) Charlotte M Niemeyer et al.   NATURE GENETICS

c-Cbl acts as a mediator of Src-induced activation of the PI3K-Akt signal transduction pathway during TRAIL treatment

(2009) Jae J. Song et al.   CELLULAR SIGNALLING

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

(2009) G. D. Demetri et al.   CLINICAL CANCER RESEARCH

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms

(2009) Masashi Sanada et al.   NATURE

RAS Pathway Mutations in Juvenile Myelomonocytic Leukemia

(2008) Peter D. Emanuel   ACTA HAEMATOLOGICA

Differential ubiquitin binding of the UBA domains from human c-Cbl and Cbl-b: NMR structural and biochemical insights

(2008) Zi-Ren Zhou et al.   PROTEIN SCIENCE